Seeking Alpha
 

Abbott Laboratories (ABT)

- NYSE
Show Summaries  |  Hide Summaries
  • Dec. 30, 2014, 4:09 PM
  • Oct. 22, 2014, 7:42 AM
    | Comment!
  • Jan. 6, 2014, 2:09 PM
    | 3 Comments
  • Dec. 18, 2013, 3:17 PM
  • Oct. 16, 2013, 8:15 AM
  • Oct. 7, 2013, 8:41 AM
  • Sep. 25, 2013, 3:08 PM
  • Aug. 22, 2013, 12:30 PM
  • Jul. 10, 2013, 12:31 PM
    Mead Johnson Nutrition (MJN +3.8%) finally caves-in to pressure and says it will reduce the ex-factory price of its main products by 7% - 15% as of July 16. China's Bureau of Price Supervision and Anti-Monopoly recently launched an investigation into price-fixing in the infant formula market, prompting other firms such as Abbott Labs (ABT), Nestle (NSRGY.PK) and Danone to already reduce prices.
    | Comment!
  • Jul. 2, 2013, 2:27 PM
    Shares of Mead Johnson Nutrition (MJN -6.1%) responds to reports that it, as well as other companies, are under investigation in China for possible antitrust violations. The company says it's committed to providing high-quality and safe products at a good value for consumers in China and throughout the world, and it's fully cooperating with the Chinese government antitrust review of resale prices in the infant formula market and will provide information in response to inquiries received from government officials.
    | Comment!
  • Jun. 7, 2013, 1:24 PM
    Jefferies is out with some price target revisions and color after conducting a "global pharma review." Rundown: Top U.S. pick Abbott Laboratories (ABT +1.9%) reiterated at Buy, PT lowered to $44 from $46; top global pick Novartis (NVS +0.3%) has "positive growth inflection potential" in FY14; AbbVie (ABBV +0.6%), Roche (RHHBY.OB +2.5%), and Sanofi (SNY +0.5%) offer "attractive entry points" but ABBV's PT is lowered to $51 from $54; Johnson & Johnson's (JNJ +0.2%) PT lowered to $91 from $97; Merck (MRK -0.3%) has its price target raised to $56 from $54 and Pfizer (PFE +1.3%) has its target lowered slightly to $32. (Previous: Jefferies SOTP analysis)
    | 3 Comments
  • May 28, 2013, 2:42 PM
    More from Jefferies' "proprietary sum of the parts analysis" of big pharma: Price target on Bristol Myers Squibb (BMY +0.7%) raised to $53.50 from $45, Buy rating reiterated; price target on Johnson & Johnson (JNJ +0.6%) raised to $97 from $90, reiterated at Hold; AbbVie (ABBV -0.5%) reiterated at Buy, price target raised to $54 from $51; Novartis (NVS -1.5%) is "top European pick"; price target for Abbott (ABT +1.3%), the "top U.S. pick", is raised to $46 from $43. (More big pharma: DB upgrades GSK)
    | 1 Comment
  • May 6, 2013, 1:36 PM
    Merck (MRK -1.3%) gets no love today from the FDA's approval of Liptruxet late Friday, as the stock is likely dragged down with the rest of the big pharma names on the back of a CNBC report that criticizes their earnings so far. The article points to the fact that pharmaceutical companies have seen a 4.7% contraction in earnings, and a 3.2% drop in revenue this quarter. Why? Morningstar's Damien Cover says there are two primary reasons: FX impact, especially from the yen, and intensified generic competition from patent losses.
    | Comment!
  • Apr. 10, 2013, 10:31 AM
    BG Medicine (BGMD +3.6%) trades up after announcing earlier that partner Abbott (ABT +0.2%) has obtained a CE Mark for its Galectin-3 assay run on the Architect immunochemistry platform. The Galectin-3 assay is an indicator that assesses the risk for readmission in heart failure. BGMD is partnering with four diagnostic instrument manufacturers to commercialize automated versions of the test, making it available in several European countries, pending country registration.
    | Comment!
  • Feb. 15, 2013, 10:43 AM
    Shares of Abbott Labs (ABT +1%) tick higher after being initiated by analysts at Stifel Nicolaus with a Buy and a price target of $40 per share, noting that the drug giant is a solid performer that delivers reliable and consistent earnings growth.
    | Comment!
  • Jan. 23, 2013, 7:51 AM
    Abbott Labs (ABT): Q4 EPS of $1.51 beats by $0.01. Revenue of $10.84B beats by $0.26B. Shares +3% premarket. (PR)
    | 1 Comment
Visit Seeking Alpha's
ABT vs. ETF Alternatives
Company Description
Abbott Laboratories discovers, develops, manufactures and sells health care products. Its products include branded generic pharmaceuticals manufactured internationally, marketed and sold outside the United States.